SCHEMBL18239343

SCHEMBL18239343

CC(C)(C)OC(=O)N1C[C@@H]2CCCN[C@@H]2C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
HPGD P15428 1/20 0.41
PREP P48147 2/20 0.41
GPR119 Q8TDV5 4/20 0.40
EPHX1 P07099 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
LIPE Q05469 1/20 0.38
PARP1 P09874 1/20 0.38
MBTD1 Q05BQ5 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
KDM4E B2RXH2 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22689240 1.00 NR1H2 (0.49) NR1H2HPGDPREPGPR119EPHX1
SCHEMBL22695207 1.00 NR1H2 (0.49) NR1H2HPGDPREPGPR119EPHX1
SCHEMBL3650512 1.00 NR1H2 (0.49) NR1H2HPGDPREPGPR119EPHX1
SCHEMBL29208875 1.00 NR1H2 (0.49) NR1H2HPGDPREPGPR119EPHX1
SCHEMBL31200554 0.92 HPGD (0.46) NR1H2HPGDPREPGPR119EPHX1
SCHEMBL23663758 0.91 NR1H2 (0.51) NR1H2HPGDPREPGPR119DDB1
SCHEMBL22010186 0.91 NR1H2 (0.51) NR1H2HPGDPREPGPR119DDB1
SCHEMBL1135431 0.91 NR1H2 (0.51) NR1H2HPGDPREPGPR119DDB1
SCHEMBL4900183 0.91 NR1H2 (0.51) NR1H2HPGDPREPGPR119DDB1
SCHEMBL1135376 0.91 NR1H2 (0.51) NR1H2HPGDPREPGPR119DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL R&D INVEST S A (PT) 2022-12-22 US disclosed
US-9949976-B2 Kinase inhibitor and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2018-04-24 US disclosed
US-9796701-B2 Kinase inhibitor and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2017-10-24 US disclosed
US-20160332989-A1 Kinase Inhibitor And Use Thereof Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH2, ASAH1, GBA1 NR1H2 3126/4885HPGD 515/4885PREP 76/4885
US-20160332989-A1 Kinase Inhibitor And Use Thereof CDK4, CDK6, CDK3 NR1H2 3595/4885HPGD 2131/4885PREP 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.